iSonea teams with uHealth for AirSonea push

iSonea (ASX:ISN) has teamed up with Sydney-based digital healthcare company uHealth to help find new sales pathways for handheld wheeze-rate monitoring device AirSonea.

As part of the partnership deal, uHealth will pursue AirSonea sales and distribution opportunities in pharmacies across Australia, and also seek to educate pharmacists and GPs about the product.

uHealth will also take responsibility for overseeing the ordering process and managing device distribution in Australia.

Both companies will also conduct research into the benefits of AirSonea, with the goal of establishing the technology as a standard of care for asthma patients.

uHealth CEO Jeff Reid said the company plans to work with peak bodies, government organisations and industry groups to incorporate AirSonea into pharmacy-based asthma management programs.

“We look forward to aggressively pursuing new sales channels for the innovative AirSonea product by harnessing our strengths and connections in the national pharmacy arena,” he said.

iSonea launched AirSonea in Australia last month after securing TGA approval in August. A key feature of the product is it allows users to track their wheeze rates via smartphones through the company’s AsthmaSense app.

iSonea (ASX:ISN) shares were trading 2.38% lower at $0.615 as of around 12.30 pm on Wednesday.